NAO.VNS: A New Personalized Neural Stimulation Therapy For Drug-resistant Epilepsybroad
NAO.VNS · Horizon Europe grant · 2023-03-01–2025-08-31
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2022-ACCELERATOR-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2022-ACCELERATOROPEN-01. CORDIS record →
Objective
19.5M world population suffer from Drug-Resistant Epilepsy (DRE) with symptoms poorly controlled. 8M are not eligible for brain surgery. Vagus nerve stimulation is nowadays the best treatment option. But unfortunately, current solutions do not reply to the clinical need. They cannot adapt to each patient making the patient's therapeutic journey complicated and expensive.We created NAO.VNS, the next-generation implantable vagus nerve neurostimulator. We replaced metal wires by optical fibres to convert optical energy to electrical impulses rendering the device compliant with MRI & brain scans essential for disease diagnosis or treatment. Through NAO.VNS, patients & physicians receive remote feedback on the direct effect & efficacy of the neural stimulation, to precisely & uniquely adapt therapy.Through EIC funding, we will complete a clinical pilot trial & a pivotal study in the EU/US to initiate market approvals. We expect to generate €89M by 2028 selling in the EU/US.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| SYNERGIA MEDICAL | BE | coordinator | €2,499,000 | Yes |
Get the EU Defence Funding Calendar — free
The full calendar of open EU defence and dual-use funding calls, sorted by deadline, updated nightly. Delivered with DFM Analysis, our weekly briefing on who is funding what in European defence.
Or browse all open defence & dual-use calls on the funding calendar →
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; the paid Annual Professional subscription is handled on DFM Analysis.